- Price
- $193.46
- Day
- +6.03%
- Mkt Cap
- $41.13B
- 52W Range
- $34.00 – $194.56
- Volume
- 1.61M
- Beta
- 1.40
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
First Trust Advisors LP grew its holdings in shares of Revolution Medicines, Inc. (NASDAQ: RVMD) by 80.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 70,970 shares of the company's stock after acquiring an additional 31,605 shares
Read full article
This billionaire investor is betting big on a revolutionary approach in treating pancreatic cancer.
Read full article
Avidity Partners Management LP bought a new position in shares of Revolution Medicines, Inc. (NASDAQ: RVMD) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 15,000 shares of the company's stock, valued at approximately $1,459,000. Several other large investors
Read full article
But is that performance sustainable?
Read full article
REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the second quarter of 2026 on Wednesday, August 5, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.
Read full article
Revolution Medicines' FDA filing for daraxonrasib in metastatic pancreatic cancer enters an accelerated review program, bringing its first commercial product closer.
Read full article
California Public Employees Retirement System trimmed its holdings in Revolution Medicines, Inc. (NASDAQ: RVMD) by 3.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 281,960 shares of the company's stock after selling 9,046 shares during the quarter. California Public Employees Retirement
Read full article
REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the company's New Drug Application (NDA) for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).
Read full article
Bessemer Group Inc. reduced its holdings in Revolution Medicines, Inc. (NASDAQ: RVMD) by 59.2% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 48,062 shares of the company's stock after selling 69,600 shares during the period. Bessemer Group Inc.'s
Read full article
Revolution Medicines aims to replace chemotherapy with target treatments. Its positive Phase 3 findings could pave the way towards its regulatory approval.
Read full article